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Abstract: After a violent episode, a 47-year-old Japanese man with chronic treatment-resistant
schizophrenia was admitted to our hospital and treated with conventional antipsychotics. After
3 years, olanzapine was added. Four days later, he lost consciousness and blood tests revealed
marked hypoglycemia, increased insulin levels, and a homeostasis model assessment of insulin
resistance of 2.5. He recovered rapidly after intravenous injection of glucose. He had no history
of loss of consciousness, was not obese and did not have any risk factors for hypoglycemia.
Similar episodes occurred in the early morning of the fifth and sixth days following the olanzapine
administration. Each time there was the same response to intravenous glucose. Olanzapine was
discontinued on the seventh day and, after one year, replaced by risperidone. Since then (2 years
ago), his schizophrenic symptoms have been in partial remission and he has had no further
hypoglycemic episodes. In view of the possible induction of hypoglycemia with olanazapine,
even in the absence of any risk factors, and in the absence of any major differences in efficacy,
it is a reasonable strategy to select an agent such as risperidone which has more favorable side-
effect profile.
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Olanzapine is known to cause hyperglycemia and hyperlipidaemia. The mechanism of
these metabolic abnormalities is still unclear. We present a case of hypoglycemia which
suggests that olanzapine affects insulin secretion.
A Japanese man (aged 47) with chronic schizophrenia had delusions and
hallucinations that were refractory to treatment and was repeatedly admitted to
psychiatric hospitals. He had become violent toward his family and was admitted to
Seiwakai-Kitsunan Hospital as a long-term in-patient and treated with haloperidol
12 mg/day, levomepromazine 150 mg/day, flunitrazepam 2 mg/day, and biperiden
3 mg/day, without side-effects for 3 years.
In view of the lack of improvement in the patient’s psychiatric condition, it was
decided to add an atypical antipsychotic agent to the treatment regimen and olanzapine
was introduced (10 mg nocte) after blood tests showed no metabolic abnormalities
(case 1, Table 1). Four days later, he suddenly lost consciousness  in the morning, while
walking in the ward, but did not appear to have a seizure. A blood sample was taken
while he was unconscious and revealed severe hypoglycemia and elevated insulin levels
while triglycerides were normal (Table 1). A bolus injection of 20 mL 50% glucose
was administered intravenously and he rapidly regained consciousness. Similar episodes
occurred in the early morning of the fifth and sixth days following the onset of treatment
with olanzapine. Each time there was the same response to intravenous glucose. The
patient did not have a history of loss of consciousness or seizures, his body mass index
(BMI) was 19.8, and he did not have any conditions associated with hypoglycemia,
such as gastrectomy or hepatic dysfunction. Electroencephalography revealed no
abnormalities.Neuropsychiatric Disease and Treatment 2006:2(4) 584
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Olanzapine was withdrawn on the seventh day and there
were no further episodes of hypoglycemia or loss of
consciousness (Table 1). Treatment with the conventional
antipsychotics continued for approximately 1 year, at which
time risperidone, an atypical antipsychotic agent, was
introduced (2 mL oral solution (1 mg/mL nocte) to the
regimen and for the past 2 years his chronic schizophrenia
has been in partial remission on 3 mL daily. There have been
no hypoglycemic episodes for 3 years and fasting blood tests
do not show any abnormalities (Table 1). Biochemical data
from two other patients (cases 2 and 3) who developed
asymptomatic hypoglycemia while taking olanzapine at this
hospital are also shown in Table 1.
Olanzapine is known to cause hyperglycemia and elevated
triglyceride levels. In a recently published randomized
controlled trial with discontinuation of antipsychotic agents
as an indicator of intolerance, discontinuation because of
weight increase and metabolic abnormalities was significantly
more common for olanzapine (Lieberman et al 2005) than
for other antipsychotics. Osser et al (1999) suggested that the
metabolic abnormalities caused by olanzapine are usually
related to weight gain and the associated insulin resistance.
In the present case, however, olanzapine resulted in
hypoglycemia, not hyperglycemia, and it may be that there is
a common metabolic abnormality; namely, olanzapine-
induced insulin resistance. In the present case, insulin levels
were elevated during the episodes of hypoglycemia following
each dose of olanzapine, which suggests the possibility of
delayed insulin hypersecretion.
Evidence for direct metabolic effects of olanzapine has
been provided by a study (Newcomer et al 2002) in which
insulin resistance was measured by homeostasis model
Table 1  Metabolic markers prior to, during, and after olanzapine treatment
Case 1
a Case 2 Case 3
Gender Male Male Male
Age (years) 52 58 44
BMI 19.8 18.8 19.6
Height (cm) 154 158 153
Weight (kg) 47 47 46
Medication prior to olanzapine HAL 12 mg; LP 150 mg; RIS 4 mg RIS 4 mg
Olanzapine dose 10 mg 5 mg 15 mg
Loss of consciousness Yes No No
Fasting plasma glucose (mg/dL)
Before olanzapine 86 85 84
On olanzapine 44 57 64
After olanzapine withdrawal 87 – –
and the addition (1 year later)
of risperidone 3 mg
Fasting serum insulin (µ µ µ µ µU/mL)
Before olanzapine 5 5 4
On olanzapine 23 17 40
After olanzapine withdrawal 6 – –
and the addition (1 year later)
of risperidone 3 mg
Insulin resistance (HOMA)
Before olanzapine 1.06 1.05 0.83
On olanzapine 2.50 2.39 6.32
After olanzapine withdrawal 1.29 – –
and the addition (1 year later)
of risperidone 3 mg
Fasting plasma triglyceride (mg/dL)
Before olanzapine 92 69 90
On olanzapine 88 64 83
After olanzapine withdrawal 96 – –
and the addition (1 year later)
of risperidone 3 mg
acase described in this paper
Abbreviations: BMI, body mass index; HAL, haloperidol; HOMA, homeostasis model assessment; LP, levomepromazine; RIS, risperidone.Neuropsychiatric Disease and Treatment 2006:2(4) 585
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assessment (HOMA-IR) after oral glucose tolerance testing,
adjusting for BMI and eliminating weight increase as a factor.
They showed that in comparison to risperidone and
conventional antipsychotics, clozapine and olanzapine caused
insulin resistance (Newcomer et al 2002). In a study in non-
obese, non-diabetic subjects, Henderson et al (2005) found
that HOMA-IR and leptin levels were elevated following
treatment with clozapine and olanzapine, again indicating
insulin resistance. Using frequently sampled intravenous
glucose tolerance test (FSIVGTT) and calculating insulin
sensitivity indices using minimal model analysis they found
that insulin sensitivity was significantly lower with clozapine
and olanzapine treatment than with risperidone. They
considered that before causing obesity, olanzapine induces
insulin resistance.
Thus from the above studies olanzapine would be expected
to promote insulin secretion. In the case presented here the
patient experienced episodes of hypoglycemia, not
hyperglycemia, and each time his insulin levels were high,
and as a result the HOMA-IR was high. In an in vitro
experiment, Melkersson (2004) exposed pancreatic beta-cells
to clozapine and olanzapine and found that both agents
directly induced insulin secretion. To our knowledge, we
report here the first case of hypoglycemia associated with
insulin hypersecretion.
Usually, even if olanzapine stimulates insulin secretion,
homeostatic mechanisms act to regulate blood sugar levels
and prevent the onset of hypoglycemia. The present patient is
slim, with low fasting blood glucose and triglyceride levels,
so he may lack reserve capacity with regard to glucose
homeostasis, which may be the reason why he developed
hypoglycemia early in the morning before breakfast. Although
the clinical presentation was a series of hypoglycemic
episodes, the HOMA-IR was higher than at other times,
indicating the underlying problem was insulin resistance. The
patient was successfully switched to risperidone oral solution
1 year later, without recurrence of hypoglycemia, suggesting
that the hypoglycemic episodes were a direct metabolic effect
of olanzapine.
Although biochemical data are not available after
olanzapine discontinuation, two other patients at this hospital
have experienced asymptomatic hypoglycemic episodes
associated with olanzapine (Table 1). All three cases of
hypoglycemia were males of slim build, with low blood
glucose and triglyceride levels prior to starting on olanzapine.
Although it may initially appear paradoxical, the possibility
of metabolic abnormalities, particularly hypoglycemia, should
be considered in the early stages of introducing olanzapine
to the treatment regimen of slim, male patients. Indeed, it
could be argued that a systematic search for indicators of
insulin resistance should be carried out in all slim male patients
within a few days of starting olanzapine after having
established baseline values before treatment.
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